SEC Form 4 · accession 0001144204-17-008146
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phil Skolnick
Officer — Chief Scientific Officer
Period of report
Feb 6, 2017
Accepted (ET)
Feb 13, 2017 · 9:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.00 | Feb 6, 2017 | A | 200,000 | A | Aug 6, 2018 | Feb 6, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1On February 6, 2017, the reporting person was granted an option to purchase 200,000 shares of common stock. The option vests as follows: (i) 100,000 shares vest on the eighteen-month anniversary of the date of grant; (ii) 5,555 shares vest on each of the nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth and twenty-sixth month anniversaries of the date of grant; and (iii) 5,556 shares vest on each of the twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second, thirty-third, thirty-fourth, thirty-fifth and thirty-sixth month anniversaries of the date of grant, becoming fully vested on the three-year anniversary of the date of grant.